Video

Study finds UGN-102 well-tolerated in patients with NMIBC

Author(s):

Urology Times staff

In this video, William C. Huang, MD, discusses the findings and takeaways of a recent phase 2b trial published in the Journal of Urology, which investigates the agent UGN-102 as a treatment for patients with non–muscle-invasive bladder cancer (NMIBC). Huang is a professor in the departments of urology and radiology at the New York University Grossman School of Medicine and the chief of urology at Tisch Hospital, New York City.

Related Videos
1 expert is featured in this series.
Related Content
FDA logo
December 6th 2024

FDA grants priority review to durvalumab for muscle-invasive bladder cancer

Benjamin P. Saylor
The priority review decision is based on results of the phase 3 NIAGARA study (NCT03732677).
medical depiction of bladder cancer
May 31st 2023

Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care

Urology Times staff
In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.
Pembro/chemo combo shows promise in small cell/neuroendocrine bladder and prostate cancer
December 2nd 2024

Pembro/chemo combo shows promise in small cell/neuroendocrine bladder and prostate cancer

Hannah Clarke
“The combination of pembrolizumab and chemotherapy presents a promising new treatment approach for these challenging-to-treat, rare cancers and could be a major breakthrough for patient care,” says Arnold I. Chin, MD, PhD.
Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
December 7th 2021

Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app

Urology Times staff
“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.
QUILT 3.032 trial: Anktiva achieves high response rate in BCG-unresponsive NMIBC
November 19th 2024

QUILT 3.032 trial: Anktiva achieves high response rate in BCG-unresponsive NMIBC

Hannah Clarke
At the time of data cutoff, 71% of patients achieved a complete response following treatment.
Cretostimogene grenadenorepvec plus nivolumab shows promise in cisplatin-ineligible MIBC
November 11th 2024

Cretostimogene grenadenorepvec plus nivolumab shows promise in cisplatin-ineligible MIBC

Hannah Clarke
"Together, the data point to the exciting potential for this combination regimen to be used to treat patients with muscle invasive bladder cancer," says Roger Li, MD.
© 2024 MJH Life Sciences

All rights reserved.